Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System
NR may reduce 30-day COVID-19 healthcare utilization costs, but the high cost of purchasing NR is likely to exceed those savings. Price reductions are necessary for NR to be a financially viable treatment for healthcare systems. Risk-informed allocation strategies can help maximize treatment benefits and minimize budget increases.
Authors
- Lei Yan (ORCID: https://orcid.org/0000-0002-4779-2688)
- George N. Ioannou (ORCID: https://orcid.org/0000-0003-1796-8977)
- Mihaela Aslan (ORCID: https://orcid.org/0000-0002-5041-010X)
- Kristin Berry (ORCID: https://orcid.org/0009-0000-7372-7727)
- Denise M. Hynes
- Nallakkandi Rajeevan (ORCID: https://orcid.org/0000-0002-2045-0872)
- Diana J. Govier (ORCID: https://orcid.org/0000-0002-3643-3540)
- David Bui (ORCID: https://orcid.org/0000-0003-0861-0850)
- Kristina L. Bajema (ORCID: https://orcid.org/0000-0002-3229-5590)
- Yuli Li (ORCID: https://orcid.org/0000-0003-1364-8562)
- Edwin S. Wong (ORCID: https://orcid.org/0000-0002-6079-686X)
- Hung‐Mo Lin (ORCID: https://orcid.org/0000-0003-3176-6570)
- Yuan Huang
- Robert Vergun
Institutions
- Oregon State University (US)
- Oregon Health & Science University (US)
- University of Washington (US)
- Veterans Health Administration (US)
- Portland VA Medical Center (US)
- Yale University (US)
- VA Connecticut Healthcare System (US)
- VA Puget Sound Health Care System (US)
- VA Portland Health Care System (US)
- Department of Veterans Affairs (AU)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/ofid/ofaf596
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- U.S. Department of Veterans Affairs
- Biomedical Advanced Research and Development Authority